1
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, S Tarran Jones, Ted A Yednock: Humanized antibodies against leukocyte adhesion molecule VLA-4. Athena Neurosciences, Townsend & Townsend & Crew, November 24, 1998: US05840299 (77 worldwide citation)

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.


2
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, Tarran S Jones, Ted A Yednock: Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies. Elan Pharmaceuticals, Crowell & Moring, August 21, 2012: US08246958 (31 worldwide citation)

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host ...


3
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, Tarran S Jones, Ted A Yednock: Humanized anti-VLA4 immunoglobulins. Elan Pharaceuticals, Crowell & Moring, October 14, 2008: US07435802 (6 worldwide citation)

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host ...


4
Laurence A Lasky, Steven D Rosen, Scott E Stachel, Mark S Singer, Ted A Yednock: DNA sequence encoding a functional domain of a lymphocyte homing receptor. Genentech, The Regents of the University of California, Ginger R Dreger, Carolyn R Adler, March 24, 1992: US05098833 (111 worldwide citation)

DNA isolates coding for a lymphocyte homing receptor and methods of obtaining such DNA are provided, together with expression systems for recombinant production of the lymphocyte homing receptor useful in therapeutic or diagnostic compositions.


5
Laurence A Lasky, Steven D Rosen, Scott E Stachel, Mark S Singer, Ted A Yednock: Lymphocyte homing receptors. Genentech, Ginger R Dreger, June 1, 1993: US05216131 (61 worldwide citation)

DNA isolates coding for the lymphocyte homing receptor and methods of obtaining such DNA are provided, together with expression systems for recombinant production of the lymphocyte homing receptor useful in therapeutic or diagnostic compositions.


6
Laurence A Lasky, Scott E Stachel, Steven D Rosen, Mark S Singer, Ted A Yednock: Lymphocyte homing receptors. Genentech, Merchant & Gould PC, October 12, 2006: US20060229435-A1

DNA isolates coding for the lymphocyte homing receptor and methods of obtaining such DNA are provided, together with expression systems for recombinant production of the lymphocyte homing receptor useful in therapeutic or diagnostic compositions.


7
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, Tarran S Jones, Ted A Yednock: Humanized anti-VLA 4 immunoglobulins and uses thereof. Elan Pharmaceuticals, Buchanan Ingersoll PC, May 25, 2006: US20060110394-A1

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host ...


8
Tarran Jones
Mary M Bendig, Olivier J Leger, Jose Saldanha, Tarran S Jones, Ted A Yednock: Therapeutic uses of humanized antibodies against alpha-4 integrin. Elan Pharmaceuticals, Crowell & Moring, April 1, 2010: US20100081793-A1

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host ...



Click the thumbnails below to visualize the patent trend.